Indeed, the CLL cells that redistribute and survive in the peripheral blood during continued therapy with ibrutinib selectively recover and maintain functionally competent IgM on the cell surface [66]. This evidence concerns the gene CD40LG and B-cell chronic lymphocytic leukemia.